Roth Capital Maintains Buy on Casper Sleep, Lowers Price Target to $12
Roth Capital analyst Matt Koranda maintains Casper Sleep (NYSE:CSPR) with a Buy and lowers the price target from $14 to $12.
85 Biggest Movers From Yesterday
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
Casper Sleep Stock Plunges After Q2 Results, Lower Margins, Weak Outlook
Casper Sleep Inc (NYSE:CSPR) reported second-quarter FY21 revenue growth of 37.7% year-on-year, to $151.76 million, marginally ahead of the analyst consensus…
54 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
Recap: Casper Sleep Q2 Earnings
Shares of Casper Sleep (NYSE:CSPR) rose 2.6% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 32.79% year over year to ($0.81), which missed the estimate of ($0.34).
Casper Sleep Q2 EPS $(0.81) Misses $(0.34) Estimate, Sales $151.76M Beat $151.28M Estimate
Casper Sleep (NYSE:CSPR) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.34) by 138.24 percent. This is a 32.79 percent decrease over losses of $(0.61) per share from the
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell
• Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.
Investing In Coinbase, Robinhood Early: Is Nas The Best Rapper Turned Investor?
Nas sold over 15 million records in the U.S. during his professional career as a rapper and songwriter. The rapper may go down in history as one of the greatest singers/rappers turned investors of all time.